Management of multiple myeloma in Asia: resource-stratified guidelines
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Tan, Daryl | - |
dc.contributor.author | Chng, Wee Joo | - |
dc.contributor.author | Chou, Takaaki | - |
dc.contributor.author | Nawarawong, Weerasak | - |
dc.contributor.author | Hwang, Shang-Yi | - |
dc.contributor.author | Chim, Chor Sang | - |
dc.contributor.author | Chen, Wenming | - |
dc.contributor.author | Durie, Brian G. M. | - |
dc.contributor.author | Lee, Jae Hoon | - |
dc.date.available | 2020-02-28T22:43:36Z | - |
dc.date.created | 2020-02-06 | - |
dc.date.issued | 2013-11 | - |
dc.identifier.issn | 1470-2045 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/gachon/handle/2020.sw.gachon/14152 | - |
dc.description.abstract | Treatment of multiple myeloma has undergone substantial developments in the past 10 years. The introduction of novel drugs has changed the treatment of the disease and substantially improved survival outcomes. Clinical practice guidelines based on evidence have been developed to provide recommendations on standard treatment approaches. However, the guidelines do not take into account resource limitations encountered by developing countries. The huge disparities in economy, health-care infrastructure, and access to novel drugs in Asian countries hinder the delivery of optimum care to every patient with multiple myeloma in Asia. In this Review we outline the guidelines that correspond with different levels of health-care resources and expertise, with the aim to unify diagnostic and therapeutic guidelines and help with the design of future studies in Asia. | - |
dc.language | 영어 | - |
dc.language.iso | en | - |
dc.publisher | ELSEVIER SCIENCE INC | - |
dc.relation.isPartOf | LANCET ONCOLOGY | - |
dc.subject | STEM-CELL TRANSPLANTATION | - |
dc.subject | INTERNATIONAL STAGING SYSTEM | - |
dc.subject | GROUP CONSENSUS STATEMENT | - |
dc.subject | IN-SITU HYBRIDIZATION | - |
dc.subject | HIGH-DOSE THERAPY | - |
dc.subject | UNDETERMINED SIGNIFICANCE | - |
dc.subject | MONOCLONAL GAMMOPATHY | - |
dc.subject | RANDOMIZED-TRIAL | - |
dc.subject | STANDARD CHEMOTHERAPY | - |
dc.subject | PERIPHERAL NEUROPATHY | - |
dc.title | Management of multiple myeloma in Asia: resource-stratified guidelines | - |
dc.type | Article | - |
dc.type.rims | ART | - |
dc.description.journalClass | 1 | - |
dc.identifier.wosid | 000326275300024 | - |
dc.identifier.doi | 10.1016/S1470-2045(13)70404-2 | - |
dc.identifier.bibliographicCitation | LANCET ONCOLOGY, v.14, no.12, pp.E571 - E581 | - |
dc.identifier.scopusid | 2-s2.0-84886685262 | - |
dc.citation.endPage | E581 | - |
dc.citation.startPage | E571 | - |
dc.citation.title | LANCET ONCOLOGY | - |
dc.citation.volume | 14 | - |
dc.citation.number | 12 | - |
dc.contributor.affiliatedAuthor | Lee, Jae Hoon | - |
dc.type.docType | Review | - |
dc.subject.keywordPlus | STEM-CELL TRANSPLANTATION | - |
dc.subject.keywordPlus | INTERNATIONAL STAGING SYSTEM | - |
dc.subject.keywordPlus | GROUP CONSENSUS STATEMENT | - |
dc.subject.keywordPlus | IN-SITU HYBRIDIZATION | - |
dc.subject.keywordPlus | HIGH-DOSE THERAPY | - |
dc.subject.keywordPlus | UNDETERMINED SIGNIFICANCE | - |
dc.subject.keywordPlus | MONOCLONAL GAMMOPATHY | - |
dc.subject.keywordPlus | RANDOMIZED-TRIAL | - |
dc.subject.keywordPlus | STANDARD CHEMOTHERAPY | - |
dc.subject.keywordPlus | PERIPHERAL NEUROPATHY | - |
dc.relation.journalResearchArea | Oncology | - |
dc.relation.journalWebOfScienceCategory | Oncology | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
1342, Seongnam-daero, Sujeong-gu, Seongnam-si, Gyeonggi-do, Republic of Korea(13120)031-750-5114
COPYRIGHT 2020 Gachon University All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.